Information for site staff
Every COVID-19 patient in the UK may be invited to participate in the RECOVERY Trial. Randomisation includes the following arms: usual care alone; REGN-COV2 monoclonal antibodies; aspirin, colchicine, baricitinib and dimethyl fumarate. The trial is designed to have the least possible impact on NHS staff. You will find Frequently Asked Questions on the site set-up page.
See Update Alerts on this page for update details.
5 March 2021
On the recommendation of the trial Data Monitoring Committee, colchicine has been removed from the RECOVERY trial randomisation. Further information is available on the news page and in a letter sent to investigators.
24 February 2021
Substantial amendment 16 has been implemented today. We will provide additional information about dimethyl fumarate shortly.
The RECOVERY Trial protocol is available for use by investigators everywhere to design their own randomised trials that could help identify effective treatments for COVID-19.